CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Brentuximab Vedotin (Adcetris) for Peripheral T-cell Lymphoma

Project Number PC0199-000
Brand Name Adcetris
Generic Name Brentuximab Vedotin
Strength 50 mg / vial
Tumour Type Lymphoma
Indication Peripheral T-cell Lymphoma (PTCL)
Funding Request For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).
Review Status Complete
Pre Noc Submission Yes
NOC Date November 22, 2019
Manufacturer Seattle Genetics, Inc.
Sponsor Seattle Genetics, Inc.
Submission Date October 8, 2019
Submission Deemed Complete October 23, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ October 23, 2019
Check-point meeting January 7, 2020
pERC Meeting March 19, 2020
Initial Recommendation Issued April 2, 2020
Feedback Deadline ‡ April 17, 2020
pERC Reconsideration Meeting May 21, 2020
Final Recommendation Issued June 4, 2020
Notification to Implement Issued June 19, 2020
Therapeutic Area peripheral T-cell lymphoma (PTCL)
Recommendation Type Reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.